Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway.
about
Effect of Metformin on Different Non-Diabetes Related Conditions, a Special Focus on Malignant Conditions: Review of Literature.Protopanaxadiol and metformin synergistically inhibit estrogen-mediated proliferation and anti-autophagy effects in endometrial cancer cellsMetformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.Trifluoperazine prevents FOXO1 nuclear excretion and reverses doxorubicin-resistance in the SHG44/DOX drug-resistant glioma cell lineMetformin as a Therapeutic Target in Endometrial Cancers
P2860
Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metformin inhibits estrogen-de ...... the AMPK-FOXO1 signal pathway.
@en
Metformin inhibits estrogen-de ...... the AMPK-FOXO1 signal pathway.
@nl
type
label
Metformin inhibits estrogen-de ...... the AMPK-FOXO1 signal pathway.
@en
Metformin inhibits estrogen-de ...... the AMPK-FOXO1 signal pathway.
@nl
prefLabel
Metformin inhibits estrogen-de ...... the AMPK-FOXO1 signal pathway.
@en
Metformin inhibits estrogen-de ...... the AMPK-FOXO1 signal pathway.
@nl
P2093
P2860
P356
P1433
P1476
Metformin inhibits estrogen-de ...... the AMPK-FOXO1 signal pathway.
@en
P2093
Chaohuan Luo
Huier Yuan
Jidong Cheng
Jiexiong Huang
Jingfang Zou
Liangli Hong
Tengfei Wen
Tianliang Huang
Wanling Zhuang
P2860
P304
P356
10.1111/CAS.13083
P577
2016-09-16T00:00:00Z